OPKO Health Inc. (NASDAQ: OPK) saw its stock price plummet by 5.44% on November 7th, 2024, following the release of the company's third-quarter financial results for the year 2024.
The biopharmaceutical and diagnostics company reported adjusted losses of $0.09 per share for the quarter, matching analysts' consensus estimates. However, the company's quarterly sales of $173.6 million fell short of analysts' expectations of $181.525 million, missing the mark by 4.37%. Furthermore, the reported sales figure represented a 2.8% decline compared to the same period in the previous year.
The disappointing sales performance, which fell below both analyst projections and the company's own year-ago results, appears to be the primary driver behind OPKO Health's stock price decline. Investors may have reacted negatively to the weaker-than-expected revenue growth, which could raise concerns about the company's business momentum and future prospects.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.